Syncromune appoints Zhihong Li as head of regulatory affairs

US clinical-stage biotech Syncromune today announced the appointment of Zhihong Li as chief regulatory affairs officer.

Dr Li brings 18 years of regulatory and drug development experience spanning the US Food and Drug Administration, Pfizer (NYSE: PFE), Biocytogen/Eucure and Belief Biomed.

In his new post, Dr LI will oversee global regulatory strategy, ensuring compliance with FDA, European Medicines Agency and China’s National Medical Products Administration requirements, and is expected to play a key role in advancing SYNC-T Therapy SV-102 through late-stage clinical development.